霍亂疫苗市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cholera Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月09日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於霍亂發病率上升以及對其公共衛生影響的認知不斷提高，霍亂疫苗市場規模預計在 2024 年至 2032 年期間複合年成長率達到 8.4%。

據世界衛生組織稱，2023 年，霍亂影響了超過 667,000 人，導致 4,000 人死亡。這種疾病仍然是許多發展中地區的一個緊迫問題，特別是在缺乏衛生設施和供水的地區。霍亂的頻繁爆發往往因自然災害和衝突而加劇，這凸顯了迫切需要進行有效的疫苗接種活動來遏制疾病的傳播。

創新已經為更有效、更持久的疫苗、加強保護和最大限度地減少接種頻率鋪平了道路。新疫苗配方的推出，加上口服疫苗等增強的給藥方法，簡化了資源有限環境中的給藥，推動了市場的擴張。

整個產業分為產品、最終用戶和地區。

從產品來看，Vaxchora 領域的霍亂疫苗市場規模預計到2032 年將產生可觀的收入。疫苗。這種獨特的口服製劑提供了一種方便有效的霍亂防護方法，滿足了旅行前免疫的巨大需求。

就最終用戶而言，由於個人和組織對預防性醫療解決方案的認知和需求不斷增加，私營部門的霍亂疫苗市場價值預計在 2024 年至 2032 年期間將出現強勁的複合年成長率。私人醫療保健提供者和機構擴大提供霍亂疫苗接種服務，作為其預防保健和旅行健康計劃的一部分。

由於霍亂疫情的高發生率以及與衛生和水質相關的持續公共衛生挑戰，亞太地區霍亂疫苗產業規模將在 2024 年至 2032 年間大幅成長。快速的都市化、人口成長和環境因素導致霍亂的傳播，進一步需要強而有力的疫苗接種工作。政府和非政府組織加強改善弱勢社區的衛生基礎設施和疾病預防舉措，提高了疫苗的使用率，促進了區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 霍亂疫情的發生率不斷增加。
  - 政府支持不斷增加
  - 擴大研究經費和活動
  - 前往流行地區的旅行不斷增加
- 產業陷阱與挑戰
  - 無法獲得足夠的治療
  - 冷鏈要求
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
杜科拉爾
瓦克斯喬拉
Euvichol/Euvichol-Plus
其他產品

第 6 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
民眾
私人的

第 7 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 英國
- 法國
- 西班牙
- 荷蘭
- 比利時
- 克羅埃西亞
- 歐洲其他地區
亞太地區
- 印度
- 孟加拉
- 巴基斯坦
- 菲律賓
- 亞太地區其他地區
拉丁美洲
- 哥倫比亞
- 秘魯
- 智利
- 拉丁美洲其他地區
中東和非洲
- 敘利亞
- 烏干達
- 葉門
- 肯亞
- 辛巴威
- 中東和非洲其他地區

第 8 章：公司簡介

Bavarian Nordic A/S
Bharat Biotech
Biological E
EuBiologics Co. Ltd.
Hilleman Laboratories
Incepta Pharmaceuticals Ltd.
Shantha Biotechnics (Sanofi)
Vabiotech
Valneva Sweden AB

簡介目錄

Product Code: 10163

Cholera vaccines market size is set to record an 8.4% CAGR during 2024-2032 driven by the rising incidence of cholera and heightened awareness of its public health implications.

According to the WHO, in 2023, cholera affected over 667,000 individuals, leading to 4,000 reported fatalities. The disease remains a pressing concern in numerous developing regions, especially where sanitation and water supply are lacking. Frequent cholera outbreaks, often intensified by natural disasters and conflicts, underscore the urgent need for effective vaccination campaigns to curb the spread of the disease.

Innovations have made way for more effective, longer-lasting vaccines, bolstering protection and minimizing the frequency of doses. The introduction of new vaccine formulations, coupled with enhanced delivery methods like oral vaccines that simplify administration in resource-limited settings fuels the market expansion.

The overall industry is segmented into product, end-user, and region.

Based on product, the cholera vaccines market size from the Vaxchora segment is expected to generate notable revenue by 2032. This is due to its role as the first and only FDA-approved oral cholera vaccine specifically designed for travelers to endemic regions. This unique oral formulation offers a convenient and effective means of protection against cholera, addressing a significant need for pre-travel immunization.

In terms of end-user, the cholera vaccines market value from the private segment is projected to observe a robust CAGR during 2024 - 2032 owing to the increasing awareness and demand for preventive healthcare solutions among individuals and organizations. Private healthcare providers and institutions are increasingly offering cholera vaccination services as part of their preventive care and travel health programs.

Asia Pacific cholera vaccines industry size will grow substantially between 2024 and 2032 attributed to the high incidence of cholera outbreaks and ongoing public health challenges related to sanitation and water quality. Rapid urbanization, population growth, and environmental factors contribute to the spread of cholera, further necessitating robust vaccination efforts. The increased government and NGO initiatives focused on improving health infrastructure and disease prevention in vulnerable communities are boosting vaccine uptake, adding to the regional market growth.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculations
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cholera outbreaks.
  - 3.2.1.2 Growing governments support
  - 3.2.1.3 Expanding research funding and activities
  - 3.2.1.4 Growing travel to endemic regions
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of access to adequate treatment
  - 3.2.2.2 Cold chain requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Dukoral
5.3 Vaxchora
5.4 Euvichol/Euvichol-Plus
5.5 Other products

Chapter 6 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Public
6.3 Private

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 UK
- 7.3.2 France
- 7.3.3 Spain
- 7.3.4 Netherlands
- 7.3.5 Belgium
- 7.3.6 Croatia
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 India
- 7.4.2 Bangladesh
- 7.4.3 Pakistan
- 7.4.4 Philippines
- 7.4.5 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Columbia
- 7.5.2 Peru
- 7.5.3 Chile
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 Syria
- 7.6.2 Uganda
- 7.6.3 Yemen
- 7.6.4 Kenya
- 7.6.5 Zimbabwe
- 7.6.6 Rest of Middle East and Africa